Drugmakers Slow-Walk New Products to Dodge Biden’s Pricing Law

Drugmakers are slow-walking products to market to get around President Joe Biden’s plan to lower medication prices.

Companies from Roche Holding AG to biotech Alnylam Pharmaceuticals Inc. are among those delaying or evaluating therapies in light of the government’s new ability to negotiate for lower prices. Firms that normally try to sell drugs as soon as possible are suspending clinical trials and shifting timelines, while patient groups are demanding change.

Intended to trim costs for Medicare, the US health program for seniors, Biden’s Inflation Reduction Act has sparked both ire and lawsuits from manufacturers claiming it will eat into ...